Amycretin (zenagamtide)
Also known as: zenagamtide
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Novo Nordisk |
| Mechanism | Unimolecular GLP-1 + amylin dual agonist |
| Administration | Once-daily oral tablet OR once-weekly subcutaneous injection |
| Peak weight loss | ~22% subq at 36 weeks / ~13.1% oral at 12 weeks (Phase 1) |
| Status | Phase 3 for obesity initiated Q1 2026 |
Deep dive
What Is Amycretin? Novo Nordisk's Oral GLP-1/Amylin Weight Loss Drug →Novo Nordisk's first-in-class GLP-1/amylin dual agonist — 13.1% weight loss as a daily pill in 12 weeks, 22% as a weekly injection in 36 weeks.
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.